Marizyme, Inc. CEO David Barthel joins WTR’s Tim Regan and Matt Borsch to provide an introduction to Marizyme, a fast-growing biomedical company engaged in the accelerated development and commercialization of products from its multi-technology platform. A key focus for our podcast discussion was DuraGraft, which is the company’s ground-breaking flagship technology that offers a clinically-superior innovation to improve patient outcomes as well as cost efficiency associated with cardiac care, with further applications such as organ transplantation on the horizon. Recently introduced in Europe with planned implementation in the US markets pending FDA approval, DuraGraft has already gained acceptance in key EU markets backed by strong evidence for its efficacy. We discussed the company’s near-term key goals (as well as the inherent risks to navigate) that include strengthening the foundation for commercialization in US markets as well as further product innovation. Finally, we briefly touched on the CEO’s preliminary target of reaching $25 million in annual revenue by 2025 on the way to robust further growth.
